Danuglipron – Talk Bio

Actionable Insights Powered by AI

Pfizer’s Strategic Shift Post-Danuglipron: Exploring New Frontiers in Obesity Treatment

1 week ago talkbio0Tagged Danuglipron, GLP-1 receptor, GLP-1/GIP therapies, Injury of liver, Metabolic Diseases, Obesity, Pfizer, Pharmaceutical competition, pipeline, Weight-Loss Agents

Pfizer, danuglipron, obesity treatment, GLP-1 receptor agonist, liver injury, weight-loss drugs, GLP-1/GIP therapies, pharmaceutical competition, metabolic diseases, Viking Therapeutics, obesity pipeline

Pfizer Advances Development of Once-Daily Oral GLP-1 Receptor Agonist Danuglipron for Obesity Treatment

10 months ago talkbio0Tagged Clinical Trials, Danuglipron, Drug Formulation Process, Glucagon-Like Peptide-1 Receptor, Obesity, once-daily, Pfizer, Weight Loss Medication

Pfizer, Danuglipron, GLP-1 Receptor Agonist, Obesity Treatment, Once-Daily Formulation, Clinical Trials, Weight Loss Medication